Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings estimates for Stoke Therapeutics in a report released on Wednesday, November 6th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($2.00) per share for the year, up from their prior estimate of ($2.11). HC Wainwright has a "Buy" rating and a $35.00 price objective on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Stoke Therapeutics' FY2025 earnings at ($2.82) EPS, FY2026 earnings at ($2.09) EPS, FY2027 earnings at ($0.70) EPS and FY2028 earnings at $0.22 EPS.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to analysts' expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.
A number of other equities research analysts have also recently commented on STOK. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. Wedbush reiterated an "outperform" rating and issued a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $20.83.
Get Our Latest Stock Analysis on Stoke Therapeutics
Stoke Therapeutics Price Performance
Shares of NASDAQ STOK traded up $0.61 during mid-day trading on Friday, reaching $13.88. The company's stock had a trading volume of 419,252 shares, compared to its average volume of 759,820. The stock has a 50-day moving average of $13.24 and a two-hundred day moving average of $13.70. Stoke Therapeutics has a 1-year low of $3.77 and a 1-year high of $17.58.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. purchased a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $19,835,000. SG Americas Securities LLC boosted its stake in shares of Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company's stock valued at $927,000 after purchasing an additional 58,943 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Stoke Therapeutics in the first quarter worth approximately $1,224,000. Vanguard Group Inc. lifted its stake in Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company's stock worth $23,160,000 after acquiring an additional 67,052 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter.
Insiders Place Their Bets
In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company's stock, valued at $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 11.30% of the stock is currently owned by insiders.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Further Reading
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
